Press Releases

Second quarter revenue grew 37% to $76 million Consumer revenue grew 27% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co.
November 7, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial
October 24, 2022
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that management will be
October 12, 2022
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company
October 5, 2022
Chu brings over two decades of experience in product management, design and strategy, as well as expertise with navigating complex industries SUNNYVALE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today
September 19, 2022
First quarter revenue grew 9% to $64.5 million Consumer revenue grew 17% year over year due to the addition of telehealth revenue On track to achieve FY2023 financial guidance SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co.
August 8, 2022
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2023 (FY2023) first quarter after the market closes on Monday,
July 25, 2022
Displaying 1 - 10 of 19
Print Page
RSS Feeds
Email Alerts
Contact IR